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OBJECTIVES: Those elderly patients are vulnerable to digoxin toxicity due to 
their diminished organ functions and tendency to occur drug interactions with 
digoxin. The aim of this research was to describe the exposure patterns of 
prescribed Chinese Medications (CM) and its associated factors among elderly 
patients taking digoxin. METHODS: A retrospective population-based cohort 
study was conducted Longitudinal Health Insurance databases in Taiwan. Those 
elderly patients being prescribed with digoxin in outpatient settings during 2006 
were evaluated for their concurrent use of prescribed CM (prevalence, incidence 
[excluding concurrent use of CM six month prior], duration). After 1 to 4 
randomly matching for those CM-digoxin users and digoxin-along users, the 
multivariate logistic regression was performed to explore factors associated with 
concomitant CM-digoxin use and exposure to specific potential interactions. 
RESULTS: Of 185,076 elderly in 2006 in Taiwan, 6,364 (3.4%) used digoxin and 754 
(0.4%) were CM-digoxin users. Within one-year following-up, the prevalence and 
incidence of concomitant CM use among digoxin elderly users were 13.4% and 
7.1%, respectively. The average durations were 190.7±136.7 days for digoxin 
elderly users, 30.8±49.6 days for prevalent CM-digoxin users, and 17.25±23.9 days 
for incident CM-digoxin users. While other factors were not statistically 
significant associated with incident CM-digoxin use, patients with coronary 
heart diseases (CAD) increased 218% likelihood of incident CM-digoxin use. 
Those with CAD and BPH and used more health care resources tended to use 
specific CM with digoxin. CONCLUSIONS: With substantial amount of CM-
digoxin users among the elderly, further study is needed to explore the impact of 
patient outcomes on concurrent use of CM with digoxin.  
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OBJECTIVES: Venous thromboembolism (VTE) is a pathological condition 
inclusive of deep vein thrombosis (DVT) and pulmonary embolism (PE). A 
systematic review was conducted to summarize the global epidemiological 
burden and mortality of primary/recurrent VTE events across patient 
populations. METHODS: Eligible studies (both full publications and abstracts) 
were identified from an exhaustive, systematic database review. Outcomes of 
interest included incidence/prevalence of primary/recurrent VTE, mortality and 
associated risk factors. RESULTS: The estimated annual incidence rate of DVT 
and PE in the US, Europe and Asia was reported at 0.21-1.48 per 1,000 person-
years, with a prevalence of 0.2-0.66%. In the US, prevalence is estimated to 
increase from the current estimate of 0.42% to 0.57% by 2050, driven by 
population growth and increased detection. Although there was a paucity of 
Asian data, published results suggest a lower prevalence compared with Western 
countries. Risk factors for VTE include increased age, male sex, ethnicity, 
surgery, cancer, initial event type and pharmacology. VTE recurrence is 
dependent on both the initial event type and/or the presence of VTE risk factors. 
The risk of recurrence peaks 6 to 12 months following the primary event, with 5-
year cumulative recurrence estimated at ~28%. VTE-related mortality in the US 
and Europe was reported to occur in up to 370,000 patients annually and is 
estimated to account for 10% of all in-hospital deaths. The level of PE-related 
mortality was up to 60%, was dependent on underlying risk factors, and was 
markedly higher compared with DVT-related mortality. CONCLUSIONS: VTE is 
particularly prevalent in the elderly, active cancer and surgical populations with 
major additional risk factors including sex and ethnicity. VTE carries significant 
levels of mortality with the highest levels reported in care based versus 
community setting. Increased population growth and aging population 
demographic coupled with improved detection will result in an increasing health 
care burden.  
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OBJECTIVES: To assess the incidence, prevalence and cost implications of drug 
related problems in patients with chronic diseases dwelling in a local 
community METHODS: The present study was a prospective observational study 
conducted in a South Indian city residential area. Institutional ethics committee 
has approved the study. The research pharmacist recorded the details of patients 
with chronic diseases through house visits and reviewed the prescriptions of the 
enrolled patients for drug related problems with their consent. Cipolle’s 
classification was used to assess the type of DRPs. Prevalence, severity level and 
significance of DRP’s was also assessed and net societal cost burden due to the 
DRPs was also calculated. RESULTS: During the six months study period, 480 
houses were surveyed and identified 190 patients (Male: 80 and Female:110) with 
chronic diseases. A total of 80 DRPs were identified in the prescriptions with an 
incidence rate of 42%. Types of DRP were Medication errors/ non compliance (17), 
untreated indications (15) and Drug interactions (14) and ADRs (8) were the most 
commonly observed DRPs. As per the severity, 9 DRPs were major, 32 DRPs were 
moderate and 39 DRP were minor and clinically non significant. The net societal 
cost burden due to DRPs was calculated as Rs.72,04,000/-. CONCLUSIONS: The 
study concludes that, incidence of DRPs in patients with chronic diseases is 
about 42% and the net societal cost burden due to DRPs was found 
Rs.72,04,000.00.  
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OBJECTIVES: To compare real-world characteristics and medication use in heart 
failure (HF) patients with REF, Reduced Ejection Fraction (EF <45%) versus PEF, 
Preserved Ejection Fraction (EF ≥45%). METHODS: Using the General Electric, 
electronic medical record database (GE-EMR), patients with a diagnosis of 
congestive heart failure (CHF) prior to the index data, which was defined as the 
first date of ejection fraction test (index date) between January 1, 2005 and 
December 31, 2009, were identified. Additional inclusion criteria include age ≥18 
years and availability of 12 months pre- and post- index date data. Patient 
demographics, clinical profile, and medication use patterns in the 12 months 
post-index period were compared between the patients with HF- REF and HF-
PEF. Bivariate analyses were conducted to determine differences between 
groups. RESULTS: Of 15,457 patients who met inclusion criteria, 9,884 (64%) had 
HF-PEF. PEF patients were older (71.4 vs. 69.1 years; p<0.0001), more likely to be 
female (55.5% vs. 32.7%; p<0.0001), obese (2.7% vs. 1.4%; p=0.0009) and diagnosed 
with hypertension (53.3% vs. 42.7%; p=0.0013), diabetes (30.0% vs. 27.8%; p=0.04), 
atrial fibrillation (25.2% vs. 20.5%; p<0.0001), lipid disorders (47.3% vs. 43.8%; 
p=0.0079), and other cardiovascular disease (13.3% vs. 11.7%;p=0.04). Compared 
to REF, PEF patients are less likely to be treated with ACEi (27.9% vs. 40.2%; 
p<0.0001), loop diuretics (46.0% vs. 51.8%; p<0.0001), alpha-beta blockers (13.7 vs. 
41.1 %; p<0.0001) and Spironolactone (7.40 vs. 16.4%; p<0.0001) while they are 
more likely to be treated with calcium channel blockers (21.8% vs. 12.7%; 
p<0.0001). CONCLUSIONS: Compared to patients with REF, PEF patients are more 
likely to be older and have cardiovascular/metabolic comorbid conditions. 
Medication use patterns suggest that compared to REF patients, PEF patients are 
less likely to be treated with medications with HF indications and more likely to 
be treated to control their underlying hypertension.  
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OBJECTIVES: In large observational studies, eight to 12% of patients with acute 
coronary syndromes (ACS) have prevalent atrial fibrillation (AF). However, the 
determinants of subsequent ACS development in the patient population with 
incident AF have not been well described. We hypothesized that risk factors 
present at the onset of AF might identify individuals at increased risk for ACS 
over the following three years. METHODS: The 5% Medicare database was used 
to identify 18,445 patients (no ESRD, age 65+) who had new-onset AF in 2006 and 
no AF or ACS in the year prior. Medicare claims were used to identify patients 
hospitalized with any acute myocardial infarction (AMI, ICD-9-CM diagnosis code 
410, 410.X, 410.X0, or 410.X1) and unstable angina (code 411). Cumulative 
incidence was calculated for the competing risks of ACS and death. RESULTS: 
Patients who had incident AF (n=18,445) in 2006 and no ACS in the previous 12 
months had multiple comorbidities. The most prevalent comorbidities were 
hypertension (67%), coronary artery disease (33%), diabetes mellitus (26%), 
dysrhythmia (26%), dyslipidemia (24%), other cardiovascular disease (23%), heart 
failure (21%), chronic obstructive pulmonary disease (18%), and cerebrovascular 
accident/TIA (15%). Overall, 8% of new-onset AF patients experienced ACS within 
three years. The cumulative risk of developing ACS was higher in patients with 
comorbidities. For example, 6% of patients with either diabetes, HF or CAD 
developed ACS within one year; this rate increased to 11% by three years. The 
risk of developing ACS at three years increased by 5% relative to year one. 
CONCLUSIONS: Patients with new-onset AF are at risk for atherothrombotic 
adverse outcomes such as ACS in addition to their recognized increased risk for 
thromboembolic stroke. Approximately one out of every 12 patients (8%) with 
newly diagnosed AF developed ACS within three years; this risk was 
substantially increased by comorbid diabetes, heart failure, or coronary disease.  
 
PCV9  
DIABETES AND SEVERITY OF CORONARY ARTERY DISEASE: ASSESSMENT OF 
CLINICAL, EPIDEMIOLOGIC, AND ANGIOGRAPHIC CHARACTERISTICS  
Shah BS1, Deshpande SS2 
1KSV University, Gandhinagar, India, 2KB Institute of Pharmaceutical Education and Research 
(KBIPER), Gandhinagar, India  
OBJECTIVES: Evaluate and compare clinical characteristics, risk factors,  
and disease severity (on angiographic findings) among diabetic and non-diabetic 
patients with coronary artery disease (CAD). METHODS: Observational study; 
consecutive patients admitted in ICU at tertiary care hospital, underwent 
coronary angiography (CAG) and diagnosed as CAD using standard definitions 
(acute coronary syndrome [ACS] i.e. myocardial infarction [MI], or unstable 
angina [UA]; or chronic stable angina [CSA]). The data included demographic 
information, risk factors for CAD, and angiographic findings. The linear stepwise 
regression was used to assess predictor of severity (more sever [double vessel 
disease, DVD or triple vessel disease, TVD] versus less sever [minimal/non-
critical disease or single vessel disease, SVD]) of CAD. The independent variables 
